Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063108 | 0.83 | ADORA3 (0.32) | ADORA3ADORA1ADORA2AHTT | |
| SCHEMBL12002419 | 0.78 | ADORA1 (0.39) | ADORA3ADORA1ADORA2AHTT | |
| SCHEMBL14511646 | 0.72 | ALDH1A1 (0.37) | ADORA3 | |
| SCHEMBL5851367 | 0.72 | — | — | |
| SCHEMBL3703036 | 0.70 | SMPD3 (0.39) | ADORA3ADORA1ADORA2AHTT | |
| SCHEMBL21719765 | 0.68 | CSNK2A1 (0.32) | ADORA3HTT | |
| SCHEMBL21718556 | 0.68 | CSNK2A1 (0.32) | ADORA3 | |
| SCHEMBL21719296 | 0.68 | ADORA3 (0.31) | ADORA3 | |
| SCHEMBL1035879 | 0.68 | — | — | |
| SCHEMBL632155 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | ADORA3 900/4885ADORA1 1214/4885ADORA2A 267/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | ADORA3 900/4885ADORA1 1214/4885ADORA2A 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.